L'Agence nationale de la recherche Des projets pour la science

Investissements d'avenirProjets financés

Plate forme Lilloise de séquençage du génome humain pour une médecine personnalisée (LIGAN PM)

Action : Equipements d'excellence

N° de convention : 10-EQPX-0007

Informations générales

  • Référence projet : 10-EQPX-0007
  • RST : Philippe FROGUEL
  • Etablissement Coordinateur : CNRS Nord Pas-de-Calais Picardie (Lille)
  • Région du projet : Hauts de France
  • Discipline : 5 - Bio Med
  • Aide allouée : 7 988 490 €
  • Date de début du projet : 22/02/2011
  • Date de fin du projet : 31/12/2019
  • Site web du projet : http://LIGAN-PM.good.cnrs.fr/

Résumé du projet

The EQUIPEX LIGAN Personalized Medicine program (LIGAN-PM) have led to the development of a plethora of protocols in the field of genetics/genomics of human diseases. The optimization of high-speed, high-throughput, next-generation sequencing (NGS) platform in the last years, allowed us to be the first in France to develop DNA-seq with very high quality, including whole exome sequencing. For instance, the NGS team has developed and optimized protocols for high-quality, high-sensitivity, targeted DNA-seq of dozens of genes involved in monogenic diabetes or obesity using the RainDance technology. In 2015, the platform productivity was increased with the acquisition of the Illumina HiSeq 4000 sequencing system. We were actually the first in Europe to get this machine. In less than one year, we were able to perform targeted DNA-seq in more than 10,000 samples (in collaboration with Sanofi group). Furthermore, we performed whole-genome sequencing in a dozen of human DNA samples in only one week. This year, Illumina have launched a new sequencing system with even higher throughput: the NovaSeq 6000 should allow us to sequence 48 entire genomes per run (in less than one week). Ligan-PM is a scientific collaboration platform with high expertise in human genetics/genomics based on NGS. Our partnership with Genoscreen, has allowed us to answer to many service or collaboration requests. The NGS protocols developed by our respective teams have usually been published in peer-reviewed journaland our expertise has now provided a complete commercial service catalogue in NGS. Furthermore, thanks to these skills, we have recently been able to answer to the request of one of the European project DIRECT partner for the study of 1600 human microbiota samples. In collaboration with Genoscreen, we aim to further develop this question of the cross talks between the microbiome and the human host genome.    

(L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.)